Research and development of anti-Alzheimer’s disease drugs: an update from the perspective of technology flows

References

• Wu TY, Chen CP, Jinn TR. Traditional Chinese medicines and Alzheimer’s disease. Taiwanese J Obstetrics Gynecol. 2011;50(2):131–135.
   PubMed Web of Science ®Google Scholar
• Zhou S, Dong LL, He Y, et al. Acupuncture plus herbal medicine for Alzheimer’s disease: A systematic review and meta-analysis. Am J Chin Med. 2017;45(07):1327–1344.
   PubMedGoogle Scholar
• Yang WT, Zheng XW, Chen S, et al. Chinese herbal medicine for Alzheimer’s disease: clinical evidence and possible mechanism of neurogenesis. Biochem Pharmacol. 2017;141:143–155.
   PubMed Web of Science ®Google Scholar
• Epperly T, Dunay MA, Boice JL. Alzheimer disease: pharmacologic and nonpharmacologic therapies for cognitive and functional symptoms. Am Fam Physician. 2017;65(12):771–778.
   Google Scholar
• Mishra CB, Kumari S, Manral A, et al. Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem. 2017;125:736–750.
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211.
   PubMed Web of Science ®Google Scholar
• Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1–2):125–132.
   PubMed Web of Science ®Google Scholar
• Fargo KN, Aisen P, Albert M, et al. Report on the milestones for the us national plan to address Alzheimer’s disease. Alzheimer Dement. 2014;10(5):S430–S452.
   PubMed Web of Science ®Google Scholar
• Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer’s disease. Alzheimer Dementia. 2007;3(3):186–191.
   PubMed Web of Science ®Google Scholar
• Mehta D, Jackson R, Paul G, et al. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs. 2017;26(6):735–739.
   PubMed Web of Science ®Google Scholar
• Sternitzke C. Patents and publications as sources of novel and inventive knowledge. Scientometrics. 2009;79(3):551–561.
   Web of Science ®Google Scholar
• Hall BH, Jaffe A, Trajtenberg M. Market value and patent citations. RAND J Eco. 2005;36:16–38.
   Web of Science ®Google Scholar
• Cohen WM, Goto A, Nagata A, et al. R&D spillovers, patents and the incentives to innovate in Japan and the United States. Res Policy. 2002;31(8):1349–1367.
   Web of Science ®Google Scholar
• No HJ, An Y, Park Y. A structured approach to explore knowledge flows through technology-based business methods by integrating patent citation analysis and text mining. Technol Forecast Soc Chang. 2015;97:181–192.
   Web of Science ®Google Scholar
• Lee C, Cho Y, Seol H, et al. A stochastic patent citation analysis approach to assessing future technological impacts. Technol Forecast Soc Chang. 2012;79(1):16–29.
   Web of Science ®Google Scholar
• Érdi P, Makovi K, Somogyvári Z, et al. Prediction of emerging technologies based on analysis of the US patent citation network. Scientometrics. 2013;95(1):225–242.
   Web of Science ®Google Scholar
• Haythornthwaite C. Social network analysis: an approach and technique for the study of information exchange. Libr Inf Sci Res. 1996;18(4):323–342.
   Google Scholar
• Xu JC, Kong XJ, Qiu L, et al. Research and development of anti-Alzheimer’s drugs: an analysis based on technology flows measured by patent citations. Expert Opin Ther Patents. 2014;24(7):791–800.
   PubMed Web of Science ®Google Scholar
• Hu YJ, Scherngell T, Man SN, et al. Is the United States still dominant in the global pharmaceutical innovation network? PLoS One. 2013;8(11):6.
   Web of Science ®Google Scholar
• Nam Y, Barnett GA. Globalization of technology: network analysis of global patents and trademarks. Technol Forecast Soc Chang. 2011;78(8):1471–1485.
   Web of Science ®Google Scholar
• Ni JY, Wan JB, Kong XJ, et al. Pharmaceutical technology licensing: an analysis in the field of cardiovascular disease. J Pharm Innov. 2016;11(1):34–45.
   Web of Science ®Google Scholar
• Li GC, Lai R, D’Amour A, et al. Disambiguation and co-authorship networks of the US patent inventor database (1975-2010). Res Policy. 2014;43(6):941–955.
   Web of Science ®Google Scholar
• Bastian M, Heymann S, Jacomy M. Gephi: an open source software for exploring and manipulating networks. Icwsm. 2009;8:361–362.
   Google Scholar
• Misra S, Medhi B. Drug development status for Alzheimer’s disease: present scenario. Neurol Sci. 2013;34(6):831–839.
   PubMed Web of Science ®Google Scholar
• Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702–716.
   PubMed Web of Science ®Google Scholar
• Ronald B, Lars E, Ivan L, et al., inventors; Janssen Sciences Ireland UC, Wyeth LLC, assignee. Immunotherapy regimes dependent on ApoE status. United States patent US9644025. 2017 May 5.
   Google Scholar
• Yan Y, Rajiv J, Niranjan R, et al., inventors; Forest Laboratories Holdings Limited, assignee. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane. United States patent US8834924. 2014 Sep 16.
   Google Scholar
• LinShiau SY, Lin JK, inventors; National Taiwan University, assignee. Composition and method for neuroprotection against excitotoxic injury. United States patent US9011945. 2015 Apr 21.
   Google Scholar
• Shane GT, Chen CF, Din CL, et al., inventors; Center Laboratories, Inc, assignee. Method for treating neurodegenerative disorders with oral dosage formulation containing both immediate-release and sustained-release drugs. United States patent US8802143. 2014 Aug 12.
   Google Scholar
• Lee HC, Chen CF, Din CL, et al., inventors; Center Laboratories, Inc., assignee. Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders. United States patent US8815288. 2014 Aug 26.
   Google Scholar
• Gold MR, Koller H, Pyerin M, inventors; Merz Pharma Gmbh & Co. Kgaa, assignee. Process for manufacturing adamantane derivatives with high yield. United States patent US8796491. 2014 Aug 5.
   Google Scholar
• Juhl K, Marigo M, Tagmose L, et al., inventors; H. Lundbeck A/S, assignee. 2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer’s disease. United States patent US9353084. 2016 May 31.
   Google Scholar
• Glabe C. Does Alzheimer disease tilt the scales of amyloid degradation versus accumulation? Nat Med. 2000;6(2):133–135.
   PubMed Web of Science ®Google Scholar
• Bachurin SO, Bovina EV, Ustyugov AA. Drugs in clinical trials for Alzheimer’s disease: the major trends. Med Res Rev. 2017;37(5):1186–1225.
   PubMed Web of Science ®Google Scholar
• Brem A, Nylund PA, Hitchen E. Open innovation and intellectual property rights: how do SMEs benefit from patents, industrial designs, trademarks and copyrights? Manag Decis. 2017;55(6):1285–1306.
   Web of Science ®Google Scholar
• Trajtenberg M. A penny for your quotes: patent citations and the value of innovations. Rand J Econ. 1990;21:172–187.
   Web of Science ®Google Scholar
• Ambure P, Roy K. CADD modeling of multi-target drugs against Alzheimer’s disease. Curr Drug Targets. 2017;18(5):522–533.
   PubMed Web of Science ®Google Scholar
• Simoni E, Bartolini M, Abu IF, et al. Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation. Future Med Chem. 2017;9(10):953–963.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wei H, Chen S, et al., inventors; Amphastar Pharmaceuticals Inc., assignee. Methods of resolving racemic mixture to obtain (-)-huperzine a. United States patent US2016096808. 2016 Apr 7.
   Google Scholar
• Pellikaan HC, Vermeulen PS, Bender JCME, et al., inventors; Echo Pharmaceuticals B.V., assignee. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances. United States patent US9308175. 2016 Apr 12.
   Google Scholar
• Vries J, Cid MVF, Lopez AMH, et al., inventors; Echo Pharmaceuticals B.V., assignee. Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment. United States patent US9616025. 2017 Apr 11.
   Google Scholar
• Uli H, Krista M, inventors; Acadia Pharmaceuticals Inc., assignee. Co-administration of pimavanserin with other agents. United States patent US2014349976. 2014 Nov 27.
   Google Scholar
• Chiang TJ. A cost-benefit approach to patent obviousness. John’s L Rev. 2008;82:39.
   Google Scholar